VXRT Stock Price: Vaxart Inc. jumps after Q2 results, amid competitor weakness

  • NASDAQ:VXRT gains 8.66% on Wednesday, as the micro-cap biotech industry rises.
  • Operation Warp Speed funding to Johnson and Johnson gives investors hope of further payouts.
  • Vaxart has a substantial war-chest to conduct a COVID-19 vaccine trial.

NASDAQ:VXRT has added to its recent surge, gaining 8.66% on Wednesday and closing the trading session at $9.66. The share price peaked after an early morning bump up to $10.99, but Vaxart spent the remainder of the day steadily declining. As with many of their rivals in the race to find a COVID-19 vaccine, Vaxart has seen its price increase by well over 2,500% so far this year, – pushing the firm’s market cap to over $1 billion. With the firm’s quarterly earnings call scheduled for next week – investors hope to hear news on the success of their vaccine in clinical development. 

Update 2: VXRT shares are soaring on Friday, trading around $9.30 after hitting a daily high of $10.20. Earnings are keeping shares bid while worries about competitors' vaccines may also be in play, especially those with links to China, as Sino-American tensions are deteriorating See Reports US to sanction Hong Kong leader Carrie Lam.  

Update: Vaxart is set to kick off Friday's trading session with a substantial double-digit rebound, recapturing the $10 level. The veteran company sai it had $140 million in cash at the end of July and that is it is preparing to enter a Phase 1 clinical trial with its coronavirus vaccine candidate. The upbeat news is inspiring investors, despite fierce competition, from firms such as Novavax. See:  NVAX, which has three reasons to rise.

The big news of the day in the coronavirus news space has been that Johnson and Johnson (NYSE:JNJ) has agreed to provide 100 million doses of their coronavirus vaccine to Americans by 2021. The deal with the federal government is estimated to be valued at $1 billion. With the global demand for a COVID-19 vaccine at an all-time high, investors are optimistic that other companies would also be receiving government funding for their vaccine candidates. While Vaxart has five versions of its oral vaccine still in clinical trials, the firm’s candidate was selected as one of the vaccines that may be provided to Americans in 2021. Adding Vaxart’s continued involvement with Johnson and Johnson on an influenza vaccine  – it is becoming clear why investors are excited about this relationship. 

Vaxart Stock Forecast

As its earnings call approaches, Vaxart investors will want to know about the prospects of its oral vaccine – and how close the company is to potential distribution. Nevertheless, investors would be wise to temper their expectations of the company, as most of the Operation Warp Speed funding could be given to big-name companies like Johnson and Johnson or Glaxosmithkline (NYSE:GSK) and Pfizer (NYSE:PFE)  – the latter also agreed to a deal to provide vaccines to Canada.

Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.

Feed news

Latest Forex News

Latest Forex News

Editors’ Picks

EUR/USD hits the highest in a month on stimulus hopes

EUR/USD has advanced toward 1.1850, reaching the highest since mid-September. US lawmakers have reportedly narrowed the gap in stimulus talks. The safe-haven dollar is on the back foot and investors are shrugging off concerns about new European COVID-19 cases.


GBP/USD bounces on better market mood

GBP/USD has recaptured the 1.2950 level after a call between Brexit negotiators was labeled as constructive. PM Johnson is set to put the Greater Manchester area under lockdown and US fiscal stimulus talks are eyed.


XAU/USD struggles for direction, stuck in a range near $1900 mark

Gold extended its sideways consolidative price moves through the early North American session and remained confined in a narrow trading band, around the $1900 mark.

Gold News

US Markets React: Gold gains, equities and dollar tumble on stimulus jitters

The stimulus election minute, the most popular dance in Washington, went through another few elaborate rounds on Capitol Hill today with Nancy Pelosi's office reporting progress in afternoon talks with Steven Mnuchin.

Read more

WTI extends the consolidation around $40.00 ahead of API

Prices of the barrel of WTI extend the consolidative mood for yet another session on Tuesday, always around the key $40.00 level.

Oil News